Key result
Mitoxantrone therapy in multiple sclerosis patients was associated with a 2.18% incidence of asymptomatic LVEF <50%, which trended higher with cumulative doses ≥100 mg/m2 (5.0% vs 1.8%, p=0.06).
Why the study?
What is the incidence of cardiotoxicity (CHF and LVEF reduction) associated with single-agent mitoxantrone therapy in patients with MS?
Population
1,378 patients with multiple sclerosis (MS) from three clinical trials
Design
Cohort
Follow-up
median 29 months
Authors
Loading...
Supports LVEF monitoring with mitoxantrone in MS; leaves open dose-threshold confirmation in prospective studies.
Observational (n=1,378)
What is the incidence of cardiotoxicity (CHF and LVEF reduction) associated with single-agent mitoxantrone therapy in patients with MS?
Single-agent mitoxantrone therapy for MS is associated with a low incidence of clinical CHF (<0.20%) and asymptomatic LVEF reduction (2.18%) at a median follow-up of 29 months, though risk may increase at higher cumulative doses.
Ghalie et al. (2002) conducted an observational in Multiple Sclerosis (n=1,378). Mitoxantrone was evaluated on Asymptomatic LVEF <50% (95% CI 1.28 to 3.47). Mitoxantrone therapy in multiple sclerosis patients was associated with a 2.18% incidence of asymptomatic LVEF <50%, which trended higher with cumulative doses ≥100 mg/m2 (5.0% vs 1.8%, p=0.06).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: